The prophylactic anti‐TIM3 treatment for HNSCC mice could suppress the tumorigenesis, and blockade of TIM3 notably improved immune response with increased populations of CD4+ and CD8+ T cells through modulating the CD4+TIM3+ cells and CD8+TIM3+ cells. The gene discussed is CD8A; the disease is head and neck squamous cell carcinoma.